EUCTR2004-002534-18-DE进行中（未招募）不适用
An open, multicenter study to evaluate the efficacy and safety of a 4 week therapy with CoDiovan 160/25 (fixed dose combination of valsartan 160 mg plus HCTZ 25 mg) in patients not adequately responding to a 4 week monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan medoxomil 20 mg plus HCTZ 12.5 mg - VALORY
ovartis Pharma GmbH0 个研究点开始时间: 2004年10月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients >= 18 years
- •2. Females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods (e.g. barrier method with spermicide, intra-uterine device, hormonal contraceptives).
- •3. Patients with essential hypertension:
- •- At Visit 1, untreated patients should have a MSDBP >= 100 mmHg and < 110 mmHg and treated patients need to have a MSDBP < 110 mmHg. Untreated patients can be included as soon as the safety laboratory parameters are available, but not at the day of Visit 1. This inclusion visit will be recorded as Visit 3 in the CRF.
- •- At Visit 2, patients previously treated for hypertension need to have a MSDBP >= 100 mmHg and < 110 mmHg for entrance into the first treatment phase. Patients previously treated for hypertension who have a MSDBP < 100 mmHg at Visit 2 will continue the wash-out phase and will be again evaluated with regard to BP criteria at Visit 3. Untreated patients do not perform Visit 2.
- •- At Visit 3, which is not performed for patients who entered the first treatment phase already at Visit 2, patients need to have a MSDBP >= 100 mmHg and < 110 mmHg for entrance into the first treatment phase.
- •- At Visit 4, all patients need to have a MSDBP >= 90 mmHg for entrance into the second treatment phase
- •4. Written informed consent to participate in the study prior to any study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. MSDBP >= 110 mmHg or MSSBP >= 180 mmHg
- •2. Pregnant or nursing women
- •3. Treated hypertensive patients with controlled hypertension under current therapy (MSDBP < 90 mmHg and MSSBP < 140 mmHg)
- •4. History of hypertensive encephalopathy or cerebrovascular accident within the preceding 12 months
- •5. Evidence of a secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral renal artery stenosis or pheochromocytoma
- •6. Known or suspected contraindications including history of allergy to angiotensin II receptor blockers or to diuretics as described in the basic product information (particularly olmesartan medoxomil 20 mg or 40 mg, valsartan 160 mg)
- •7. Heart failure NYHA II-IV
- •8. Concomitant refractory angina pectoris, potentially life-threatening arrhythmia or symptomatic arrhythmia or clinically significant valvular heart disease
- •9. Transient ischemic cerebral attack, stroke or myocardial infarction during the last 12 months prior to Visit 1
- •10. Type 1 diabetes mellitus or poorly controlled Type 2 DM
- •11. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
- •12. Patient with history of malignancy of any organ system, treated or untreated, within the past five years, whether or not evidence of local recurrence or metastases exists, are excluded, with the exception of localized basal cell carcinoma of the skin
- •13. Participation in any investigational drug trial within one month prior to Visit 1
研究者
相似试验
进行中（未招募）
不适用
An open-label, multicenter study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura (ITP)Immune thrombocytopenic purpura (ITP) is the most common autoimmune disease. It is a bleeding disorder characterized by decreased counts of circulating platelets and normal or increased numbers of megakaryocytes in the bone marrow.EUCTR2004-000537-11-DEZLB Behring AG60
进行中（未招募）
不适用
An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinibEUCTR2008-000357-35-GBovartis Pharma GmbH
进行中（未招募）
不适用
An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib - NDEUCTR2008-000357-35-ITOVARTIS FARMA206
进行中（未招募）
不适用
An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinibEUCTR2008-000357-35-DEovartis Pharma GmbH
进行中（未招募）
不适用
An open label, multi-center study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura ITPEUCTR2004-000537-11-ITZLB BEHRING60